细胞色素P450 1A1基因多态性对奥沙利铂联合卡培他滨方案治疗结直肠癌患者临床疗效的影响

目的: 探讨细胞色素450（CYP450）酶的基因变异是否是奥沙利铂联合卡培他滨的方案在结直肠癌患者中的治疗结果差异的影响因素。方法: 研究入组69例接受奥沙利铂联合卡培他滨方案治疗的结直肠癌（colorectal cancer,CRC）患者，同时对细胞色素450（CYP450）基因上最小等位基因频率（MAF）≥10%的79个多态性位点进行基因分型。对这些单核苷酸多态性（SNP）位点和治疗反应率以及预后的相关性进行分析。结果: 发现仅CYP1A1的rs1048943（Ile462Val）和无进展生存期（PFS）显著相关（P=0.0003），其他位点和治疗反应率以及总生存期（OS）无明显相关性。纳入Cox风险比例模型当中校正之后，发现该位点是影响PFS独立的预后指标（P=0.004）。结论: CYP1A1上的多态性位点rs1048943（Ile462Val）对接受奥沙利铂联合卡培他滨方案治疗的CRC患者来说可能是一个可以预测预后的独立指标。

Influence of CYP1A1 polymorphism on clinical outcomes of CRC patients treated by oxaliplatin plus capecitabine

AIM: To investigate whether gene variants of cytochrome P450 (CYP450) affected clinical outcomes of oxaliplatin plus capecitabine in colorectal cancer (CRC). METHODS: Sixty-nine CRC patients who were treated with oxaliplatin plus capecitabine were included in this study. And 79 SNPs in CYP450, whose minor allele frequency (MAF) were >10% were genotyped. Association between the SNP and clinical outcomes were analyzed. RESULTS: Only one SNP, CYP1A1 rs1048943 was significantly associated with PFS (P=0.000 3). Multivariate analysis confirmed its prognostic significance for PFS (P=0.004). CONCLUSION: CYP1A1 rs1048943 polymorphism is probably a potential prognostic marker for survival outcome treated with oxaliplatin plus capecitabine chemotherapy in CRC patients.